JP6928605B2 - Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 - Google Patents

Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 Download PDF

Info

Publication number
JP6928605B2
JP6928605B2 JP2018525730A JP2018525730A JP6928605B2 JP 6928605 B2 JP6928605 B2 JP 6928605B2 JP 2018525730 A JP2018525730 A JP 2018525730A JP 2018525730 A JP2018525730 A JP 2018525730A JP 6928605 B2 JP6928605 B2 JP 6928605B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
added
nmr
δppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018525730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534314A (ja
JP2018534314A5 (enExample
Inventor
ジョン ジェームズ ウィンター−ホルト
ジョン ジェームズ ウィンター−ホルト
エドワード ジャイルズ マクアイヴァー
エドワード ジャイルズ マクアイヴァー
マーティン アンブラー
マーティン アンブラー
スティーヴン ルイス
スティーヴン ルイス
ジョアンヌ オズボーン
ジョアンヌ オズボーン
ケイリー ウェッブ−スミス
ケイリー ウェッブ−スミス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeArc filed Critical LifeArc
Publication of JP2018534314A publication Critical patent/JP2018534314A/ja
Publication of JP2018534314A5 publication Critical patent/JP2018534314A5/ja
Application granted granted Critical
Publication of JP6928605B2 publication Critical patent/JP6928605B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018525730A 2015-11-20 2016-11-16 Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 Expired - Fee Related JP6928605B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1520500.8A GB201520500D0 (en) 2015-11-20 2015-11-20 Compounds
GB1520500.8 2015-11-20
PCT/GB2016/053580 WO2017085484A1 (en) 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021019390A Division JP7181647B2 (ja) 2015-11-20 2021-02-09 Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2018534314A JP2018534314A (ja) 2018-11-22
JP2018534314A5 JP2018534314A5 (enExample) 2019-12-26
JP6928605B2 true JP6928605B2 (ja) 2021-09-01

Family

ID=55133106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018525730A Expired - Fee Related JP6928605B2 (ja) 2015-11-20 2016-11-16 Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体
JP2021019390A Expired - Fee Related JP7181647B2 (ja) 2015-11-20 2021-02-09 Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021019390A Expired - Fee Related JP7181647B2 (ja) 2015-11-20 2021-02-09 Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体

Country Status (9)

Country Link
US (2) US10669284B2 (enExample)
EP (2) EP3939981B1 (enExample)
JP (2) JP6928605B2 (enExample)
CN (1) CN108495855B (enExample)
AU (1) AU2016355104B2 (enExample)
CA (2) CA3240011A1 (enExample)
ES (2) ES2981048T3 (enExample)
GB (1) GB201520500D0 (enExample)
WO (1) WO2017085484A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
DK3582776T3 (da) 2017-02-14 2024-01-08 Effector Therapeutics Inc Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
EP3870178A4 (en) 2018-10-24 2022-08-03 Effector Therapeutics Inc. Crystalline forms of mnk inhibitors
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用
WO2022006331A2 (en) * 2020-06-30 2022-01-06 4E Therapeutics, Inc. Pyridine-1,5-diones exhibitng mnk inhibition and their method of use
CN118146134B (zh) * 2024-02-07 2026-07-07 南方海洋科学与工程广东省实验室(湛江) 一种3-羟基吡咯烷衍生物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US20050153989A1 (en) 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
JPWO2005095419A1 (ja) 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2008057402A2 (en) * 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
CA2706203A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
BRPI0918971A2 (pt) * 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2562959T3 (es) * 2010-02-26 2016-03-09 Evotec International Gmbh Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
MX2012009735A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
CN102002044A (zh) * 2010-09-29 2011-04-06 中国药科大学 嘌呤-8-酮类及噻唑并嘧啶类衍生物及其制备方法和医药用途
US9556181B2 (en) 2013-02-01 2017-01-31 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
HK1220972A1 (zh) 2013-03-06 2017-05-19 Bayer Pharma Aktiengesellschaft 取代的噻唑并嘧啶
CN105531279A (zh) * 2013-07-08 2016-04-27 拜耳制药股份公司 取代的吡唑并吡啶胺

Also Published As

Publication number Publication date
JP2018534314A (ja) 2018-11-22
US10669284B2 (en) 2020-06-02
EP3377501B1 (en) 2021-08-18
CN108495855B (zh) 2022-05-31
WO2017085484A1 (en) 2017-05-26
EP3939981A1 (en) 2022-01-19
AU2016355104B2 (en) 2021-01-28
EP3377501A1 (en) 2018-09-26
US11136338B2 (en) 2021-10-05
CA3003559C (en) 2024-09-10
CA3240011A1 (en) 2017-05-26
JP2021073306A (ja) 2021-05-13
CA3003559A1 (en) 2017-05-26
CN108495855A (zh) 2018-09-04
HK1253575A1 (en) 2019-06-21
GB201520500D0 (en) 2016-01-06
AU2016355104A1 (en) 2018-05-24
ES2981048T3 (es) 2024-10-07
US20200247822A1 (en) 2020-08-06
JP7181647B2 (ja) 2022-12-01
ES2893154T3 (es) 2022-02-08
EP3939981B1 (en) 2024-04-03
US20180346483A1 (en) 2018-12-06
EP3939981C0 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
JP2021073306A (ja) Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体
JP2012519678A (ja) キナーゼ阻害剤として使用されるピロロピリミジン
JP2009504759A (ja) ホスホジエステラーゼ１０阻害剤
JP6946290B2 (ja) Ｍｎｋ阻害剤としてのピロロピリミジン化合物
HK40065647B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK40065647A (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK40037886A (en) Pyrropyrimidine compounds as mnks inhibitors
HK40037886B (en) Pyrropyrimidine compounds as mnks inhibitors
HK1253575B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
WO2025140655A1 (en) Heteroaryl compounds as multi-target protein kinase inhibitors
HK1253576B (en) Pyrropyrimidine compounds as mnks inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210806

R150 Certificate of patent or registration of utility model

Ref document number: 6928605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees